Multiple sclerosis (MS) is a progressive demyelinating and degenerative disease of the central nervous system with symptoms depending on the disease type and the site of lesions and is featured by heterogeneity of clinical expressions and responses to treatment strategies. An individualized clinical follow-up and multidisciplinary treatment is required. Transforming the population-based management of today into an individualized, personalized and precision-level management is a major goal in research. However, a complex and unique interplay between genetic background and environmental exposure in each case likely determines clinical heterogeneity. To reach insights at the individual level, extensive amount of data are required. Here, a method to revolutionize management of MS to a personalized, individualized and precision level is outlined. The key to reach this next level is FAIR data. FAIR is a fairly recent concept that stands for Findable, Accessible, Interoperable and Reusable. 1 Imagine any type of data being 'Findable, Accessible, Interoperable and Reusable' by both humans and machines. 'Findable' does not mean 'for everyone to find', 'accessible' does not mean 'open access', 'interoperable' does not mean 'for everyone to operate on' and 're-usable' 'for everyone to use'. However, it creates the possibility to find, access, interoperate and re-use data when necessary. In other words, it gives data the opportunity to have maximal impact. The possibilities to discover new insights multiplies manifold. But before we get there, many hurdles have to be overcome. Here, a 4C plan is proposed to reach this goal (Collect-Connect-Complete-Construct). An intuitive representation of this plan is represented in Figure 1 . Data are collected all over the world by different stakeholders resulting in many datasets, represented by puzzles of a face (step 1: COLLECT). Every dataset has its own weaknesses and strengths. For example, existing and emerging MS-specific data initiatives resulted in international pooling of observational clinical data (e.g. MSBase Registry, 2 
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Abstract: Multiple sclerosis (MS) is a progressive demyelinating and degenerative disease of the central nervous system with symptoms depending on the disease type and the site of lesions and is featured by heterogeneity of clinical expressions and responses to treatment strategies. An individualized clinical follow-up and multidisciplinary treatment is required. Transforming the population-based management of today into an individualized, personalized and precision-level management is a major goal in research. Indeed, a complex and unique interplay between genetic background and environmental exposure in each case likely determines clinical heterogeneity. To reach insights at the individual level, extensive amount of data are required. Many databases have been developed over the last few decades, but access to them is limited, and data are acquired in different ways and differences in definitions and indexing and software platforms preclude direct integration. Most existing (inter)national registers and IT platforms are strictly observational or focus on disease epidemiology or access to new disease modifying drugs. Here, a method to revolutionize management of MS to a personalized, individualized and precision level is outlined. The key to achieve this next level is FAIR data. 8 ). Imperfect and inaccessible 'data silos' are also present on a local level, since data on the same patients are collected by different data collectors. Indeed, every variable is ideally collected by the expert involved. For example, neurologists are the best candidate to collect diagnosis date, medication strategy and so on. However, when it comes to patient-reported outcomes, patients should be included directly in the data collection process. The same is true for nurses (e.g. weight and blood pressure), rehabilitation specialists (e.g. physical and daily functioning), psychologists (e.g. tests for cognition and depression), speech therapists (e.g. swallowing tests and speech recognition), researchers (e.g. genetic-, immunological-and lipid metabolism) and so on. Although none of these datasets are perfect (nor will they ever be), many insights could be discovered Data are collected all over the world by different stakeholders resulting in many datasets, represented by puzzles of a face (step 1: COLLECT). Every dataset has its own weaknesses and strengths. Although none of these datasets are perfect (nor will they ever be), many insights could be discovered when these datasets could be pooled and connected (step 2: CONNECT). Sometimes, the existing data are insufficient to investigate a certain question and additional data are required. Because collecting data collection is expensive and time-consuming, efforts should be as focused as possible and methods to identify the minimal requirements for common datasets are required (step 3: COMPLETE). When sufficient overlap between the databases involved is secured and powerful analytical methods are developed to cope with the imperfections of datasets featured by different layers of missing data, these datasets can be optimally mined to create new insights for MS management (step 4: CONSTRUCT).
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when these datasets could be pooled and connected (step 2: CONNECT). Indeed, in a recently approved Horizon2020 project 'MultipleMS' (www.multiplems.eu), universities and companies across Europe and the United States are connecting their datasets to tailor the development and application of therapies to the individual MS patient. Still, sometimes the existing data are insufficient to investigate a certain question and additional data are required. Because collecting data is expensive and time-consuming, efforts should be as focused as possible and methods to identify the minimal requirements for common datasets are required (step 3: COMPLETE). For example, when it comes to personalized prediction of disease progression, information on different levels is required. Collecting all these data for every patient is not feasible. But what if we could mine existing datasets to formulate guidelines for a minimal core dataset? When sufficient overlap between the databases involved is secured and powerful analytical methods are developed to cope with the imperfections of datasets featured by different layers of missing data, these datasets can be optimally mined to create new insights for MS management (step 4: CONSTRUCT).
More specifically, the following steps are formulated: Many insights can be reached using existing data. However, focussed prospective of retrospective data collection will often be required. Therefore, there is a need to develop statistical methods to define minimal requirements for datasets. Being able to objectively define these minimal requirements will make it much easier to motivate people involved in data collection to collect data that are not necessary for their initial intent. Motivating or giving incentives for the collection and storage of biological samples could already be one step forward because this makes retrospective retrieval much easier and less time-consuming.
CONSTRUCT: develop analytical methods for
optimal data mining. We lack proper analytical tools for optimal mining of datasets that are featured by different layers of missing data. New insights in building decision-support systems using a combination of imperfect datasets are required. Different research questions should be investigated here (e.g. what is the power of machine learning techniques for these applications? and how can we better handle missing data?). Table 1 summarizes some concrete recommendations on how we could implement this 4C plan in the MS data arena. Our research project MS DataConnect (www.msdataconnect.com) aims at providing proofof-concept of this 4C plan to enhance MS research. The MS DataConnect Consortium and the Belgian healthdata.be platform will collaborate to set up a multidisciplinary MS register connecting information collected by care givers, patients and researchers. User-friendly, sustainable FAIR data collection tools and procedures are developed for MS-relevant data striving towards 'the only once' -principle referring to (1) data capture from primary (operation) sources of health care actors and (2) re-use of previously collected data.
Data collection is extremely expensive and timeconsuming. Enabling data to achieve maximal impact is our duty on a social and ethical level, but also greatly decreases financial costs associated with decision-making/best practice and increased efficiency for identification of research gaps) but also benefit the researcher in many other personal ways as well (e.g. networking, increased number and impact of publication). This will lead to more motivation to contribute to the data collection and quality of the data as well, a win-win situation. 8 The future perspectives of this 4C plan are endless and depend on the stakeholders involved. Indeed, regulators need data for life-cycle assessment of medicinal products, health technology assessment bodies want to incorporate data from clinical practice into the drug development process and researchers want to build personalized decision-support systems. 
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: L.P. was supported by Interuniversity Attraction Pole (IUAP, no IAP VII/39), the MS network Limburg, the Biomedical Research Institute of Hasselt University and the ELIXIR project.
ORCID iD
Liesbet M. Peeters http://orcid.org/0000-0002-6066-3899
